Role of AT1-Receptor Blockers in Insulin-Induced Vasodilation.
Information source: Maastricht University Medical Center
Information obtained from ClinicalTrials.gov on November 03, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Hypertension; Insulin Resistance; Microcirculation
Intervention: Irbesartan (Drug); Felodipine (Drug); Placebo (Drug)
Phase: N/A
Status: Recruiting
Sponsored by: Maastricht University Medical Center Official(s) and/or principal investigator(s):
CDA Stehouwer, Prof., Study Chair, Affiliation: Univeristy Hospital Maastricht
Overall contact:
A.M. Jonk, MSc, Phone: +31 43 3881432, Email: a.jonk@intmed.unimaas.nl
Summary
In this study we hypothesize that blocking the angiotensin II AT1-receptor improves the
insulin-induced microvascular dilatation. Objectives: 1. Does blockade of the angiotensin II
AT1-receptor improve the insulin-induced microvascular effects in hypertensive patients. 2.
Does blockade of the angiotensin II AT1-receptor impair the insulin-induced microvascular
effects in normotensive control subjects?
Clinical Details
Official title: Insulin-Induced Microvascular Activity in Patients With Essential Hypertension: a Possible Role for Angiotensin II AT1-Receptor Blockers.
Study design: Basic Science, Randomized, Double Blind (Subject, Investigator), Crossover Assignment
Primary outcome: functional recruitment of capillaries in the skin
Secondary outcome: perfused capillary density in the nailfoldEndothelium- (in)dependent vasodilatation of finger skin microcirculation Density of arterioles, capillaries and venules in the bulbar conjunctiva. Diameter of arterioles and venules in the bulbar conjunctiva
Eligibility
Minimum age: 18 Years.
Maximum age: 60 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
hypertensive subjects:
1. 18-60 years
2. Caucasian
3. untreated hypertension >140/90mmHg.
normotensive subjects:
1. 18-60 years
2. Caucasian
3. Blood pressure <140/90 mmHg.
Exclusion Criteria:
1. Obesity (BMI>27kg/m2)
2. Cardiovascular disease (stroke, coronary artery disease, peripheral vascular disease,
heart failure)
3. Impaired glucose tolerance or diabetes mellitus according to the criteria of the ADA
4. Smoking
5. Alcohol use >4U/day
6. Use of medication (antihypertensive drugs, lipid lowering drugs, corticosteroids,
NNSAIDs)
7. Pregnancy
8. Wearing contact lenses
Locations and Contacts
A.M. Jonk, MSc, Phone: +31 43 3881432, Email: a.jonk@intmed.unimaas.nl
University Hospital Maastricht, Maastricht, P.O. Box 5800 6202 AZ, Netherlands; Recruiting
A.M. Jonk, MSc, Phone: +31 43 3881432, Email: a.jonk@intmed.unimaas.nl
A.J.H.M. Houben, Dr., Phone: +31 43 3882122, Email: b.houben@intmed.unimaas.nl
Additional Information
Starting date: March 2008
Ending date: July 2009
Last updated: August 26, 2008
|
